IMEXA Call Center 1-866-518-4599

Inclusion:

Signed Written Informed Consent

1. Histologically confirmed Stage III (unresectable) or Stage IV melanoma
2. Must have failed at least one systemic therapy for malignant melanoma or be intolerant to at least one prior systemic treatment. Note: Enrollees must not be eligible for a clinical study with ipilimumab
3. Subjects with brain metastases are allowed
4. Primary ocular and mucosal melanomas are allowed
5. Must be at least 28 days since treatment with chemotherapy, biochemotherapy, or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment. Must have recovered from prior surgery or radiation. Systemic corticosteroids should be eliminated or weaned to the minimum dose before starting ipilimumab treatment. Consult with the Medical Monitor for individual subjects
6. ECOG PS 0- 2
7. Life expectancy ≥ 16 weeks
8. Subjects must have the complete set of baseline (screening/baseline) radiographic images, including but not limited to brain, chest, abdomen, pelvis, and bone scans

9. Required values for initial laboratory tests:

   WBC: ≥ 2000/uL (≥ 2 x 10*9*/L) ANC: ≥ 1000/uL (≥ 1 x 10*9*/L) Platelets: ≥ 75 x 103/uL (≥ 75 x 10*9*/L) Hemoglobin: ≥ 9 g/dL (≥ 80 g/L; may be transfused) Creatinine: ≤ 2.0 x ULN AST/ALT: ≤ 2.5 x ULN for subjects without liver metastasis ≤ 5 times for liver metastases Bilirubin: ≤ 2.0 x ULN (except for subjects with Gilbert's Syndrome, who must have a total bilirubin of less than 3.0 mg/dL)

10. Men and women, at least 16 years of age

Exclusion Criteria:

1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study and for up to 8 weeks after the last dose of investigational product
2. WOCBP using a prohibited contraceptive method
3. Women who are pregnant or breastfeeding
4. Women with a positive pregnancy test on enrollment or before investigational product administration
5. Subjects on any other systemic therapy for cancer, including any other experimental treatment
6. Prior treatment with an anti CTLA 4 antibody if treatment failure was due to irAEs or discontinuation was due to an AE/SAE
7. Any subject enrolled in a registrational study (ie, CA184024) that has a survival endpoint should not be enrolled in CA184-045. Also, if a subject is eligible for a treatment study, he or she is not eligible for this study
8. Presence of active autoimmune disease
9. Presence of known hepatitis B or hepatitis C (active) infection, regardless of control on antiviral therapy
10. Subjects with melanoma who have another active, concurrent, malignant disease, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix
11. Any non-oncology vaccine therapy used for prevention of infectious diseases for up to 4 weeks before or after any dose of ipilimumab, with the exceptions of amantadine and flumadine